The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer
Official Title: NOAC9 - A Phase II Randomised Nordic Anal Cancer Group Study on Circulating Tumor DNA Guided Follow-Up
Study ID: NCT05572801
Brief Summary: This study investigates if circulating tumor DNA can improve the detection of early treatment failure or recurrence in localized squamous cell carcinoma of the anus (SCCA) after curative chemoradiotherapy thereby increasing the potential for cure. This will be done by comparing the standard follow-up program with ctDNA guided imaging follow-up. Secondly, the aim is to establish early interventions against late morbidities.
Detailed Description: Squamous cell carcinoma of the anus (SCCA) is a rare disease with less than 200 new cases in Denmark and Sweden each year and approximately 100 new cases in Norway and Finland but with increasing incidence. Primary treatment is chemo-radiotherapy (CRT) comprising high dose IMRT based radiation therapy with combination chemotherapy of 5-FU and Cisplatin. Overall treatment response is good in small tumors, but less pronounced for high-risk tumors. In absence of complete pathological response after CRT or local recurrence, patients are evaluated for. salvage surgery. The importance of R0 resection on overall survival has been described in several studies. It is suggested that early detection of treatment failure and recurrences increases the chance of possible curative surgery (R0-resection) and thereby overall survival. A follow-up program has 3 purposes 1. To detect lack of complete response to primary treatment 2. Early detection of local or distant recurrences 3. Describing and managing late morbidity Purpose: The main purpose of this follow-up study is to investigate if circulating tumor tDNA can improve detection of early treatment failure or recurrences thereby assisting in increasing the potential for cure. Secondly, to provide evidence for use of imaging and third objective is to establish early intervention against late morbidities.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Department of Oncology Herlev and Gentofte Hospital, Herlev, Capital Region Of Denmark, Denmark
Department of Oncology, Vejle Hospital, Vejle, The Regions Of Southern Denmark, Denmark
Aarhus University Hospital, Aarhus, , Denmark
Tampere University Hospital, Tampere, , Finland
Turku University Hospital, Turku, , Finland
Haukeland University Hospital, Bergen, , Norway
Oslo University Hospital, Oslo, , Norway
University Hospital of North Norway, Tromsø, , Norway
St. Olav's University Hospital, Trondheim, , Norway
Sahlgrenska University Hospital, Göteborg, , Sweden
Skåne University Hospital Lund, Lund, , Sweden
Karonlinska University Hospital, Stockholm, , Sweden
Norrlands University Hospital, Umeå, , Sweden
Name: Karen-Lise G Spindler, Professor
Affiliation: Department of Experimental Clinical Oncology Aarhus Univeristy Hospital
Role: PRINCIPAL_INVESTIGATOR